Document is current

Article History

First Online: 24 August 2017

Competing interests

: M.W.B. has received speaker's bureau from Novartis Pharmaceuticals. B.G. has acted as a consultant for Teva Pharmaceuticals, Mesoblast, Celadon, Novartis Pharmaceuticals, Janssen and AstraZeneca. J.L.J. has received research support from Roche Diagnostics, Siemens, Prevencio and Singulex; consulting income from Boehringer Ingelheim, Novartis and Janssen; and participates on cardiology endpoint committees and/or data safety monitoring boards for Boehringer Ingelheim, Bayer, Novartis, Pfizer and Janssen. C.S.P.L. has received research support from Boston Scientific, Bayer, Thermofisher, Medtronic and Vifor Pharma; and has acted as a consultant for Bayer, Novartis, Takeda, Merck, AstraZeneca, Janssen Research & Development, LLC, Menarini, Boehringer Ingelheim and Abbott Diagnostics. A.P.M. has received honoraria for the participation in committees of trials sponsored by Novartis, Bayer, Cardiorentis and Fresenius. J.-N.T. has received research grants from Novartis, Carmat and Abbott; and has consulted for Abbott, Amgen, Bayer, Carmat, Daichi, Heartware, Novartis, Vifor Pharma, Sankyo and Resmed. J.B. is a consultant for Amgen, AstraZeneca, Bayer, Boehringer Ingelheim, Bristol-Myers Squibb, CVRx, Janssen, Luitpold, Medtronic, Novartis, Relypsa and ZS Pharma. T.J. has received honoraria for the participation in committees of projects sponsored by Novartis.